About

Guanglan Zhang is the Chair of the Computer Science department at Boston University Metropolitan College, where she also serves as an Associate Professor in Computer Science. She is the Coordinator of Health Informatics Programs. Her role involves leadership within the department and contributions to the development of health informatics education and research. Specific details about her research focus, background, or key contributions are not provided in the page text.

Research topics

• Artificial Intelligence
• Computer Science
• Machine Learning
• Internal medicine
• Medicine
• Radiology
• Genetics
• Pathology
• Computational biology
• Immunology
• Biology
• Medical physics
• Virology

Selected publications

• Effects of combined oral contraceptives on steroids and lipidomics in newborns of mothers with polycystic ovary syndrome

  Reproductive BioMedicine Online · 2025-05-09 · 1 citations

  article
  PublisherDOI

• Association of specific HLA alleles in patients with interstitial cystitis suggesting autoimmunity

  Frontiers in Molecular Medicine · 2025-12-04

  articleOpen access

  Interstitial cystitis/bladder pain syndrome (IC/BPS) with Hunner Lesions (Hunner Type Interstitial Cystitis or HIC) is characterized by lesions on the bladder wall. Previous work on these lesions identified B cells and monocytes within the lesion. However, the overall role of the adaptive immune system in the disorder remains uncertain. In this study, we performed HLA sequencing on 12 IC/BPS patients with HIC and 7 Non Hunner Type IC (NHIC) patients, and identified HLA-DQB1*02:02 and HLA-DRB1*07:01:01 have a significant association with HIC. This pilot study provides genetic evidence supporting a potential autoimmune component in HIC and may help define the pathogenesis of at least one subtype of IC/BPS, and lay the groundwork for identifying the etiology of IC/BPS as a disease complex. Identifying the mechanisms can also open new approaches to treatment. Identifying an HLA haplotype associated with HIC would indicate that it is autoimmune.

  PublisherOA PDFDOI

• PD03-07 INTERSTITIAL CYSTITIS WITH HUNNER LESIONS IS ASSOCIATED WITH A SPECIFIC HUMAN LEUKOCYTE ANTIGEN ALLELE, INDICATING AN AUTOIMMUNE ETIOLOGY

  The Journal of Urology · 2025-04-08

  article
  PublisherDOI

• XKidneyOnco: An Explainable Framework to Classify Renal Oncocytoma and Chromophobe Renal Cell Carcinoma with a Small Sample Size

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-01-25 · 2 citations

  preprintOpen access

  Abstract Renal oncocytoma and chromophobe renal cell carcinoma are two kidney cancer types that present a diagnostic challenge to pathologists and other clinicians due to their microscopic similarities. While RO is a benign renal neoplasm, ChRCC is considered malignant. Therefore, the differentiation between the two is crucial. In this study, we introduce an explainable framework to accurately differentiate ChRCC from RO, histologically. Our approach examined H&E-stained images of 656 ChRCC and 720 RO, and achieved a diagnostic accuracy of 88.2%, the sensitivity of 87%, and 100% specificity for explainable AI, which either outperforms or operate on par with convolutional neural network (CNN) models. Besides, we enrolled 44 pathology experts (including pathologists and pathology trainees) to differentiate the two tumors. The average accuracy of pathologists was 73%, which is 15.2% lower than our framework. These results indicate that the combination of human expert along with explainable AI achieve higher accuracy in differentiating the two tumors, while it reduces the workload of experts and offers the desired explainability for the medical experts.

  PublisherOA PDFDOI

• Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  preprintOpen access

  Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

• Supplementary Table from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  supplementary-materialsOpen access

  Supplementary Table from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

• Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  preprintOpen access

  Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

• Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  preprintOpen access

  Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

• Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  preprintOpen access

  Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

• Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  2023-03-31

  preprintOpen access

  Supplementary Figure from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

  PublisherDOI

Frequent coauthors

• Derin B. Keskin

  Boston University

  103 shared

• Catherine J. Wu

  Harvard University

  49 shared

• Lou Chitkushev

  Boston University

  45 shared

• Donna Neuberg

  44 shared

• Livius Penter

  44 shared

• Isabel Carulli

  42 shared

• Vipheaviny Chea

  42 shared

• Teddy Huang

  Harvard University

  42 shared

Education

• Ph.D.

  Nanyang Technological University, Singapore

• Other

  Nanyang Technological University, Singapore

• B.S.

  Luoyang Institute of Technology